N myc interactor/NMI Antibody [B12H19]

Application: Reactivity: Human

Usage Information

Dilution
WB1:10000-1:50000 IP1:40-1:60 IHC1:50 IF1:100

Application
WB, IP, IHC, IF

Reactivity
Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
35 kDa 39 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
N myc interactor/NMI Antibody [B12H19] detects endogenous levels of total N myc interactor/NMI protein.

Clone
B12H19

Synonym(s)
N-myc-interactor, Nmi, N-myc and STAT interactor, NMI

Background
N‑Myc interactor (NMI) is a co-regulatory protein originally identified through its physical association with Myc family oncoproteins and STAT transcription factors and is now recognized as a cytokine‑inducible modulator of oncogenic and innate immune signaling that acts both intracellularly and, in some contexts, as a secreted damage‑associated signal. The protein lacks obvious enzymatic domains and instead contains coiled‑coil and helical regions that support hetero‑oligomeric complex formation with basic helix–loop–helix–leucine zipper transcription factors such as N‑Myc and c‑Myc and with STATs, including STAT1 and STAT5, and these interactions position NMI as a scaffold that influences transcriptional output rather than DNA‑binding specificity. NMI binds multiple STAT family members (all except STAT2) and enhances STAT‑dependent transcription in response to IL‑2 and IFN‑γ by promoting recruitment of CBP/p300 coactivators to STAT1‑ and STAT5‑containing complexes, thereby amplifying cytokine‑driven gene expression programs involved in growth control, differentiation, and immune effector function. In parallel, NMI associates with Myc proteins and with BRCA1 in a tricomplex that can repress c‑Myc‑induced hTERT promoter activity in breast cancer, and it modulates Myc‑dependent transcriptional programs that control proliferation, apoptosis, and telomerase regulation, linking NMI abundance and localization to Myc oncogenic potency. NMI also participates in Wnt/β‑catenin signaling control: enforced NMI expression upregulates the Wnt antagonist DKK1, destabilizes β‑catenin, reduces expression of β‑catenin target genes such as cyclin D1, and retards tumor cell growth, indicating that NMI can antagonize pro‑proliferative Wnt signaling and intersect with Myc‑driven networks through shared target pathways. In innate immune regulation, NMI is induced by interferons and forms a complex with IFI35 that stabilizes IFI35 and shapes type I interferon and NF‑κB outputs; ubiquitination of the NMI–IFI35 complex by TRIM21 and NMI‑dependent degradation of IRF7 attenuate virus‑triggered IFN‑β production, while secreted NMI released from injured or activated macrophages binds TLR4 on neighboring macrophages to activate NF‑κB and drive production of pro‑inflammatory cytokines, which defines NMI as both an intracellular signaling regulator and an extracellular DAMP in inflammatory microenvironments.

Background

N‑Myc interactor (NMI) is a co-regulatory protein originally identified through its physical association with Myc family oncoproteins and STAT transcription factors and is now recognized as a cytokine‑inducible modulator of oncogenic and innate immune signaling that acts both intracellularly and, in some contexts, as a secreted damage‑associated signal. The protein lacks obvious enzymatic domains and instead contains coiled‑coil and helical regions that support hetero‑oligomeric complex formation with basic helix–loop–helix–leucine zipper transcription factors such as N‑Myc and c‑Myc and with STATs, including STAT1 and STAT5, and these interactions position NMI as a scaffold that influences transcriptional output rather than DNA‑binding specificity. NMI binds multiple STAT family members (all except STAT2) and enhances STAT‑dependent transcription in response to IL‑2 and IFN‑γ by promoting recruitment of CBP/p300 coactivators to STAT1‑ and STAT5‑containing complexes, thereby amplifying cytokine‑driven gene expression programs involved in growth control, differentiation, and immune effector function. In parallel, NMI associates with Myc proteins and with BRCA1 in a tricomplex that can repress c‑Myc‑induced hTERT promoter activity in breast cancer, and it modulates Myc‑dependent transcriptional programs that control proliferation, apoptosis, and telomerase regulation, linking NMI abundance and localization to Myc oncogenic potency. NMI also participates in Wnt/β‑catenin signaling control: enforced NMI expression upregulates the Wnt antagonist DKK1, destabilizes β‑catenin, reduces expression of β‑catenin target genes such as cyclin D1, and retards tumor cell growth, indicating that NMI can antagonize pro‑proliferative Wnt signaling and intersect with Myc‑driven networks through shared target pathways. In innate immune regulation, NMI is induced by interferons and forms a complex with IFI35 that stabilizes IFI35 and shapes type I interferon and NF‑κB outputs; ubiquitination of the NMI–IFI35 complex by TRIM21 and NMI‑dependent degradation of IRF7 attenuate virus‑triggered IFN‑β production, while secreted NMI released from injured or activated macrophages binds TLR4 on neighboring macrophages to activate NF‑κB and drive production of pro‑inflammatory cytokines, which defines NMI as both an intracellular signaling regulator and an extracellular DAMP in inflammatory microenvironments.

References
https://pubmed.ncbi.nlm.nih.gov/26874464/ https://pubmed.ncbi.nlm.nih.gov/19358268/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%